Tivicay (dolutegravir) / ViiV Healthcare 
Welcome,         Profile    Billing    Logout  
 26 Diseases   58 Trials   58 Trials   4692 News 


«12...4546474849505152535455...6263»
  • ||||||||||  Use of ibalizumab in a heavily treatment-experienced HIV-1-infected subject harbouring a multidrug-resistant virus (Exhibition hall) -  Nov 15, 2019 - Abstract #EACS2019EACS_2147;    
    A Genotyping Susceptibility Tests (GSTs) was performed and, according to the Stanford HIVdb interpretation, identified: - on plasma RNA: susceptibility to doravirine (DOR)/etravirine (ETV)/rilpivirine (RPV), all integrase strand transfer inhibitors (INSTIs) and enfuvirtide (ENF); different degrees of resistance to DRV/r, all nucleoside reverse transcriptase inhibitors (NRTIs); a R5-tropic virus was found; - on blood DNA: susceptibility to DRV/r and emtricitabine (FTC)/abacavir (ABC); different degrees of resistance to tenofovir(TDF)/ABC, DOR/ETV, RPV, dolutegravir (DTG), ENF; a X4-tropic virus was found...Thanks to the “5% Fund” of the Italian Medicines Agency, this man received an initial loading dose of IBA (2000 mg/iv) followed by maintenance doses (800 mg/iv every 15 days) in association with a recycling regimen including FTC/RPV/tenofovir alafenamide 200/25/25 mg QD, DTG 50 mg BID, maraviroc 150 mg BID, ENF 90 mg BID (replaced with DRV/r 600/100 mg BID after 12 weeks to improve acceptability)...In this man IBA, plus an OBT with residual antiviral activity, favoured the achievement of virological control, at least in the short-term. Management of patients with no fully active drugs is an unmet clinical need and novel classes such as CD4-binding monoclonal antibodies may have a key role.
  • ||||||||||  Prezista (darunavir) / J&J, bictegravir (GS-9883) / Gilead, Tivicay (dolutegravir) / ViiV Healthcare
    Rapid ART start in primary HIV infection: time to viral suppression in a London cohort (Exhibition hall) -  Nov 15, 2019 - Abstract #EACS2019EACS_2074;    
    Rapid start with INSTI regimens results in quicker viral suppression than with PI-based regimens in PHI, even when PIs are subsequently switched to INSTIs. Concerns about lack of a baseline VRT result prior to rapid ART start may potentially be overcome by the use of the newer INSTIs with a high genetic barrier such as dolutegravir and bictegravir.
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare
    No evidence for induced glucuronidation of dolutegravir in HIV-infected pregnant women (Exhibition hall) -  Nov 15, 2019 - Abstract #EACS2019EACS_1928;    
    No significant difference in the molar metabolic ratio DTG-gluc AUC 0-24h /DTG AUC 0-24h in pregnancy was observed. It is unlikely that induction of UGT1A1 is the major driver of decreased DTG exposure in pregnant women.
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare
    Population pharmacokinetic analysis of dolutegravir in HIV/TB co-infected people with and without rifampicin (Exhibition hall) -  Nov 15, 2019 - Abstract #EACS2019EACS_1865;    
    P3
    A 50mg BID dose in presence of rifampicin (~2-fold induction) was adequate to achieve comparable exposure (AUC and Ctrough) to 50mg QD administration without rifampicin. The effect of covariates was not considered clinically significant, therefore, no DTG dose adjustment by these covariates is necessary.
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare
    Neurotoxicity related to efavirenz does not predict neurotoxicity related to dolutegravir (Exhibition hall) -  Nov 15, 2019 - Abstract #EACS2019EACS_1853;    
    Given the widespread use of DTG and other InSTIs prior, during, and after conception, it is imperative to further elucidate their short and long-term safety in the context of pregnancy. The history of neuropsychiatric adverse effects related to EFV does not predict the development neuropsychiatric toxicity by DTG.
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare, Vitekta (elvitegravir) / Japan Tobacco, Gilead
    Weight gain among HIV-positive persons treated with dolutegravir or elvitegravir (Exhibition hall) -  Nov 15, 2019 - Abstract #EACS2019EACS_1849;    
    This effect was less pronounced in elderly patients. On EVG, weight gain was continuous over time, whereas on DVG, weight initially increased and then stabilized.
  • ||||||||||  Predictors of weight gain in patients treated with dolutegravir (Exhibition hall) -  Nov 15, 2019 - Abstract #EACS2019EACS_1844;    
    In SCOLTA the use of TDF/FTC resulted as independent factor associated with weight gain in PLWHIV treated with DTG. Male patients with lower baseline weight and lower CD4 were those more prone to gain weight.
  • ||||||||||  lamivudine / Generic Mfg., Tivicay (dolutegravir) / ViiV Healthcare
    Lower incidence of liver steatosis in patients treated with lamivudine plus dolutegravir dual therapy (Exhibition hall) -  Nov 15, 2019 - Abstract #EACS2019EACS_1738;    
    Further accumulation of cases is considered necessary and will be studied. Although NAFLD remains a common finding in HIV-infected patients receiving ART, those on DTG + 3TC seemed less likely to develop this condition, thus suggesting a safer metabolic profile of the 2-drug regimen when compared to standard cART.
  • ||||||||||  Abacavir hipersensivity reaction (HSR), associated to baseline false negative HLAB5701 screening, in antiretroviral treatment naive HIV-1 patient (Exhibition hall) -  Nov 15, 2019 - Abstract #EACS2019EACS_1716;    
    Data of literature show that cytofluorimetric or PCR assay have the same high sensitivity to detect HLAB5701 allele,avoiding false negative tests.Cytofluorimetric is generally preferred for baseline screening,being less expensive.In contrast with these data,our case report shows a discrepancy between 2 assays,underlying that in rare cases,it is possible to obtain a false negative test,performing cytofluorimetric test. [Immunological and virological evolution] [Cd4 count and liver enzymes]
  • ||||||||||  Prezista (darunavir) / J&J, Tivicay (dolutegravir) / ViiV Healthcare
    No metabolic or renal benefits when switching to an NRTI-free dolutegravir-containing 2 drug regimen (2DR) - a subanalysis of the DUALIS study (Exhibition hall) -  Nov 15, 2019 - Abstract #EACS2019EACS_1697;    
    Purpose: The DUALIS study assessed efficacy and safety of switching to Dolutegravir (DTG) and boosted darunavir (bDRV) (2DR) and has demonstrated non-inferiority as compared to 2 NRTI+bDRV (3DR). While being non-inferior with regard to virologic suppression, a switch to a 2DR consisting of DTG+bDRV does not yield significant metabolic or renal advantages by substituting the NRTI components of a comparative 3DR antiretroviral therapy.
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare
    Switch to dolutergravir dual regimens and imflammation mediated by annexin (Exhibition hall) -  Nov 15, 2019 - Abstract #EACS2019EACS_1683;    
    Annexins levels were not altered after 48 weeks DTG-based dual therapy switch, indicating that there are no inflammatory and endothelial changes after switch. These data will be confirmed in a larger population.
  • ||||||||||  bictegravir (GS-9883) / Gilead, Tivicay (dolutegravir) / ViiV Healthcare
    Neuropsychiatric tolerability of bictegravir combined with FTC/TAF in clinical practice (Exhibition hall) -  Nov 15, 2019 - Abstract #EACS2019EACS_1643;    
    As seen with DTG, discontinuation rates were higher than in RCT. A pre-existing depression but also physician's awareness may have an impact on tolerability and continuation of BIC/F/TAF.
  • ||||||||||  Lamivudine-based maintenance 2-drugs regimens: an algorithm for the estimation of 2-years risk of virological failure in clinical practice (Exhibition hall) -  Nov 15, 2019 - Abstract #EACS2019EACS_1641;    
    From a multicentre Italian cohort of patients with undetectable HIV-RNA (according to the centre-specific threshold) and negative HBsAg-serostatus, starting lamivudine plus a bPI (darunavir, atazanavir or lopinavir) or dolutegravir, predictors of VF (i.e., a single HIV-RNA≥1000 cp/mL or 2 consecutive HIV-RNA≥50 cp/mL) at 2 years were analysed by Cox regression. Some viro-immunological characteristics of patients switching to a lamivudine-based maintenance dual-therapy can be incorporated in a useful algorithm to identify subjects at higher risk of VF.
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare
    The Treatment of Primary HIV (TopHIV) cohort: a prospective multicenter cohort in Germany (Exhibition hall) -  Nov 15, 2019 - Abstract #EACS2019EACS_1628;    
    We established a data- and biomaterial collection of a rare patient group, which allows expedited translational research. This cohort will be very valuable for future studies focussing on immune control and cure of HIV infection.
  • ||||||||||  lamivudine / Generic Mfg., Tivicay (dolutegravir) / ViiV Healthcare
    Comparing NRTI-sparing dual regimens using data from the Swiss HIV cohort study (Exhibition hall) -  Nov 15, 2019 - Abstract #EACS2019EACS_1624;    
    Estimates of relative effectiveness suggest that both dolutegravir regimens are not inferior to the alternative regimens used previously. Updated analyses show the stability of the earliest estimates with a slight gain in precision with each update.
  • ||||||||||  lamivudine / Generic Mfg., Tivicay (dolutegravir) / ViiV Healthcare
    Lamivudine-based two-drug regimens are not associated with an increased risk of detectable rectal HIV-RNA (Exhibition hall) -  Nov 15, 2019 - Abstract #EACS2019EACS_1608;    
    A cross-sectional analysis was conducted to test the association between detectable rectal HIV-RNA and the use of lamivudine plus either a boosted protease inhibitor or dolutegravir compared with TT through multivariable logistic regression. Lamivudine-based DT, compared with TT, was not associated with increased detection of rectal HIV-RNA.
  • ||||||||||  bictegravir (GS-9883) / Gilead, Tivicay (dolutegravir) / ViiV Healthcare
    In vitro analysis of replicative capacity and phenotypic susceptibility of integrase mutant HIV-2 viruses (Exhibition hall) -  Nov 15, 2019 - Abstract #EACS2019EACS_1563;    
    Through this work, we also obtained new data on the recently described 231ins resistance pathway, using site-directed mutagenesis, showing no impact on viral fitness, and confirming the decreased susceptibility to first-generation INSTI and cabotegravir. Resistance to second-generation INSTI occurred only for mutants with 5-amino-acids insertion, limiting their use in clinical practice.